Tiaprofenic acid

Generic Medicine Info
Indications and Dosage
Ankylosing spondylitis, Osteoarthritis, Pain and inflammation, Rheumatoid arthritis
Adult: 600 mg/day in 2 or 3 divided doses or once daily as modified-release preparation.
Elderly: Initiate with lowest dose.
Renal Impairment
Reduce dose to 200 mg bid. Avoid in severe impairment.
Hepatic Impairment
Reduce dose to 200 mg bid. Avoid in severe impairment.
Should be taken with food.
Hypersensitivity to other NSAID. Severe renal, hepatic impairment. Severe cardiac failure. Active peptic ulceration; urinary tract disorder, prostatic disease, history of recurrent urinary tract infection. Pregnancy (3rd trimester).
Special Precautions
Asthma, bronchospasm, bleeding disorders, CV disease, history of peptic ulceration, liver and renal function impairment, heart failure, hypertension. Discontinue use if urinary tract symptoms occur. Lactation. Elderly.
Adverse Reactions
GI disturbances, activation of peptic ulcer, hypersensitivity reactions, nephrotoxicity, cystitis, bladder irritation and other urinary tract symptoms such as frequency, dysuria and haematuria. Photosensitivity, thrombocytopenia, hepatitis, sodium and water retention. Headache, dizziness, tinnitus, drowsiness.
Potentially Fatal: GI bleed, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Drug Interactions
Potential interaction with other highly protein-bound bound drugs. Increased risk of bleeding with oral anticoagulants, antiplatelets and corticosteriods. Increased risk of toxicity with digoxin, lithium, ciclosporin and methotrexate. Decreased clearance with probenecid. May reduce antihypertensive effects of antihypertensives. May increase risk of gastric mucosal damage with biphosphonates. Increased risk of nephrotoxicity with aminoglycosides. Increased risk of convulsions with quinolones.
Description: Tiaprofenic acid is a propionic acid derivated NSAID. It acts by decreasing cyclooxygenase activity which results in decreased formation of prostaglandin precursors and inhibition of prostaglandin synthesis.
Absorption: Peak plasma concentrations: within 1.5 hr (oral).
Distribution: Protein binding: 98%. Distributed into breast milk.
Excretion: Elimination half life: 2 hr. Excreted via urine mainly as metabolites and bile.
Store below 25°C.
Disclaimer: This information is independently developed by MIMS based on Tiaprofenic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in